AVACEN Medical, with the slogan "Pain Relief from the Palm of Your Hand", is a pioneering player in the Health Care industry, focusing on non-invasive, drug-free pain management solutions since its founding in 2009. This United States-based company's flagship product, the AVACEN 100, is a patented and FDA-Cleared Class II medical device. It utilizes a unique combination of heat therapy and negative pressure, providing not just local, but widespread pain relief.
The company's recent regulatory milestone includes obtaining the CE Mark approval, enabling market entry into the European Union for treating fibromyalgia-related pain—an area where alternatives to prescription drugs are particularly sought after.
AVACEN holds four U.S. and multiple international patents protecting its innovative AVACEN Treatment Method (ATM), designed to potentially alleviate symptoms related to circulatory, neurological, lymphatic, or endocrinal dysfunctions.
The last reported investment occurred on 30 December 2014, raising $2.00M through equity crowdfunding. While AVACEN Medical presents a robust product with significant market potential, updated investment rounds and a clear strategic vision for growth could further solidify its position in the healthcare market.